HUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Current ratio
HUTCHMED (China) Limited Sponsored ADR's current ratio at the end of the quarter to 30 June 2026 was 5.6×, up 0.7× from fiscal 2025 (5.0×). Over the past ten years it has ranged from 1.1× (fiscal 2015) to 5.0× (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of 2.4× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.0× | 75.25% |
| FY2024 | 2.8× | 4.07% |
| FY2023 | 2.7× | 14.68% |
| FY2022 | 2.4× | (38.98%) |
| FY2021 | 3.9× | 16.07% |
| FY2020 | 3.4× | 19.54% |
| FY2019 | 2.8× | (35.34%) |
| FY2018 | 4.3× | 4.91% |
| FY2017 | 4.1× | 134.81% |
| FY2016 | 1.8× | 59.36% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 5.6× | 13.72% |
| Dec 2025 | 5.0× | 6.71% |
| Jun 2025 | 4.7× | 64.22% |
| Dec 2024 | 2.8× | 0.86% |
| 20 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| RGC Regencell Bioscience Holdings Limited compare | 10.8× |
| HCM HUTCHMED (China) Limited Sponsored ADR | 5.6× |
| TRLV Trulieve Cannabis Corp. compare | 5.5× |
| PBH Prestige Consumer Healthcare Inc. compare | 2.9× |
| ANIP ANI Pharmaceuticals, Inc. compare | 2.7× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.7× |
| PRGO Perrigo Company plc compare | 2.4× |
| XERS Xeris Biopharma Holdings, Inc. compare | 2.2× |
| ALVO Alvotech compare | 1.6× |
| Drug Manufacturers Specialty & Generic industry median | 2.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement